Form D · Biotechnology
Landos Biopharma, Inc.
Blacksburg, VA · CIK 0001785345
Offering snapshot reported Aug 23, 2019 · SEC filing
- Reported sold
- $60.3M Offering amount: $60.3M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 9, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 23, 2019 | Initial | $60,259,063 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-347303
Source: Form D, filed Aug 23, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Josep Bassaganya Riera | Director, Executive |
| Christopher Garabedian | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1800 Kraft Drive, Suite 216
Blacksburg, VA, 24060
Blacksburg, VA, 24060